Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lexicon

Sanofi reception

Sanofi plans to file JAK2 inhibitor after positive phase III

Aiming for approval in blood cancer myelofibrosis

- PMLiVE

Sanofi partners with PatientsLikeMe to promote its clinical trials

Online patient community will match patients to the pharma company's trials

- PMLiVE

Novo Nordisk: Strict US regulation threatens innovation

Warning from CEO Sorensen comes after Tresiba and Ryzodeg fail to win FDA approval

Sanofi reception

Sanofi fined for slamming Plavix generics

Faces €40.6m penalty for telling doctors generic copies were not suitable substitutes for blockbuster antiplatelet drug

Boehringer Ingelheim and Lilly launch diabetes education campaign

Follows the partnership’s filing of its SGLT-2 inhibitor for European approval

- PMLiVE

Sanofi appoints Pascale Witz and Peter Guenter

They will lead the pharma company's two new commercial organisations

- PMLiVE

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

Sanofi reception

Sanofi predicts return to growth in second half

But first quarter net income drops by a third

- PMLiVE

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

- PMLiVE

Merck & Co and Pfizer join forces on diabetes candidate

Latest big pharma alliance involving an SGLT2 inhibitor

- PMLiVE

Interview: Peter Meeus, Novo Nordisk

The managing director of Novo Nordisk UK discusses how education and new partnerships are helping fight the battle against the country’s worsening diabetes crisis

- PMLiVE

Boehringer: Tough HTA threatens future of German research

Drug pricing system is stifling innovation says pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links